IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

To be considered for this study, you would need to have a confirmed diagnosis of eye melanoma that has spread. Importantly, you shouldn't have received any previous treatment specifically for this advanced cancer, though some earlier treatments like surgery or radiation in a local area might be allowed.

Your general health would also be checked, including your organ function and overall well-being. You would need to be well enough to take the study medication and have a life expectancy of at least three months. There is also a specific blood test for something called HLA-A*02:01, and you would need to be negative for this marker.

Some things that might prevent you from joining include a history of other serious health conditions like certain heart problems, active infections, or if you've already had a similar type of drug. If you are pregnant or breastfeeding, you wouldn't be able to take part. The study also needs to make sure the standard treatments chosen by your doctor are suitable for you, so any reasons you couldn't take those would also be a factor.

If you join this study, you will be randomly assigned to receive either the new drug combination (IDE196 + crizotinib) or one of the standard treatments chosen by your doctor. You won't get to choose which treatment you receive. You will have regular visits to the clinic for medical check-ups, blood tests, and scans (like CT or MRI) to see how your body is responding to the treatment and if the cancer is changing. These visits will also help monitor for any side effects. The medications will be given according to a specific schedule, which your study team will explain in detail. The total duration of your participation will depend on how you respond to the treatment and the study's design, but it will involve ongoing follow-up to monitor your health.